Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on June 24, 2020. The filing addresses a strategic commercial expansion event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event under Item 8.01 (Other Events).
Material Changes
The primary material change reported is the commercial launch and immediate availability of the company's product, CytoSorb, in nine Latin American countries. The new markets include:
- Colombia
- Argentina
- Peru
- Guatemala
- Ecuador
- Bolivia
- Dominican Republic
- El Salvador
- Costa Rica
Outlook, Commentary, and Risks
Management commentary highlights that this expansion is particularly timely due to the World Health Organization's designation of Central and South American countries as "intense zones" for COVID-19 transmission. The filing does not contain specific forward-looking financial guidance, risk factors, or contingencies beyond the context of the pandemic driving demand in the new regions.
Investor Verification Checklist
- Verify the specific regulatory approvals obtained in each of the nine new Latin American markets.
- Confirm the distribution agreements and logistics capabilities established for immediate product availability.
- Assess the potential revenue impact of the expansion relative to the company's total addressable market.
- Review the attached press release (Exhibit 99.1) for detailed quotes from management regarding sales projections.